EP4704852A2 - Nanosuspensions de corticostéroïdes et leurs utilisations - Google Patents

Nanosuspensions de corticostéroïdes et leurs utilisations

Info

Publication number
EP4704852A2
EP4704852A2 EP24800432.7A EP24800432A EP4704852A2 EP 4704852 A2 EP4704852 A2 EP 4704852A2 EP 24800432 A EP24800432 A EP 24800432A EP 4704852 A2 EP4704852 A2 EP 4704852A2
Authority
EP
European Patent Office
Prior art keywords
clobetasol propionate
nanoparticles
injection
formulation
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24800432.7A
Other languages
German (de)
English (en)
Inventor
Laurene WANG
Derek J. Nunez
Jason B. COOK
Wayne W-C LIAW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AimMax Therapeutics Inc
Original Assignee
AimMax Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AimMax Therapeutics Inc filed Critical AimMax Therapeutics Inc
Publication of EP4704852A2 publication Critical patent/EP4704852A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne également des formulations en suspension de nanoparticules de propionate de clobétasol. Les suspensions peuvent être utilisées thérapeutiquement pour traiter la peau et les brûlures oculaires; pour améliorer la cicatrisation des plaies; pour prévenir ou réduire la cicatrisation/les chéloïdes hypertrophiques; pour traiter la rhinite/sinusite allergique, l'asthme, les troubles de l'oreille interne comprenant la perte auditive, l'acouphène ou le vertige, la ténosynovite, la tendinite, l'enthésite ou l'arthrite.
EP24800432.7A 2023-05-01 2024-04-30 Nanosuspensions de corticostéroïdes et leurs utilisations Pending EP4704852A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363463113P 2023-05-01 2023-05-01
PCT/US2024/026982 WO2024228993A2 (fr) 2023-05-01 2024-04-30 Nanosuspensions de corticostéroïdes et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4704852A2 true EP4704852A2 (fr) 2026-03-11

Family

ID=93333275

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24800432.7A Pending EP4704852A2 (fr) 2023-05-01 2024-04-30 Nanosuspensions de corticostéroïdes et leurs utilisations

Country Status (11)

Country Link
EP (1) EP4704852A2 (fr)
KR (1) KR20260005253A (fr)
CN (1) CN121038796A (fr)
AU (1) AU2024265712A1 (fr)
CL (1) CL2025003367A1 (fr)
CO (1) CO2025015291A2 (fr)
IL (1) IL324263A (fr)
JO (1) JOP20250270A1 (fr)
MX (1) MX2025013065A (fr)
TW (1) TW202448423A (fr)
WO (1) WO2024228993A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
HUE055016T2 (hu) * 2017-06-23 2021-10-28 Salvat Lab Sa Olaj-a-vízben nanoemulziós klobetazol készítmény

Also Published As

Publication number Publication date
CO2025015291A2 (es) 2025-11-19
KR20260005253A (ko) 2026-01-09
MX2025013065A (es) 2025-12-01
WO2024228993A2 (fr) 2024-11-07
JOP20250270A1 (ar) 2025-10-29
AU2024265712A1 (en) 2025-11-13
CN121038796A (zh) 2025-11-28
IL324263A (en) 2025-12-01
CL2025003367A1 (es) 2026-03-06
WO2024228993A3 (fr) 2025-03-20
TW202448423A (zh) 2024-12-16

Similar Documents

Publication Publication Date Title
US10918594B2 (en) Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
US20250381215A1 (en) High elasticity hyaluronan compositions and methods of use thereof
JP6209777B2 (ja) 眼の疾病及び疾患のための組成物及び治療
Chang et al. Phase II results of an intraocular steroid delivery system for cataract surgery
JPH09510961A (ja) 持続性および長期間の角膜鎮痛の方法
CN103565743B (zh) 氨甲环酸皮肤外用纳米制剂及其制备方法和用途
US20090123527A1 (en) Method of inducing topical anesthesia and transdermal patch
WO2011063606A1 (fr) Gel ophtalmique de gatifloxacine et procédé de préparation de celui-ci
KR20160047490A (ko) 소아 귀 질환의 치료
Sarchahi et al. Effect of four local anesthetics (tetracaine, proparacaine, lidocaine, and bupivacaine) on intraocular pressure in dogs
TWI878266B (zh) 治療眼表痛之方法
EP4704852A2 (fr) Nanosuspensions de corticostéroïdes et leurs utilisations
EP2424535B1 (fr) Procédés et compositions pour traiter l' oeil sec
WO2011049954A2 (fr) Compositions comprenant des modulateurs de wnt ou des neurotoxines pour le traitement de troubles otiques
JP6453318B2 (ja) 委縮性皮膚瘢痕を治療するためのプロスタグランジンＦ２α及びその類似体
CN107137698A (zh) 一种包含gdnf的用于治疗角膜上皮损伤的药物组合物
Richa et al. Promising implication of ocuserts in ocular disease
EA002267B1 (ru) Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат
TWI632913B (zh) 用於眼部疾病或異常之組合物及其治療方法
EP4442269A1 (fr) Nouvelle utilisation d'alanyl-glutamine et composition ophtalmique comprenant de l'alanyl-glutamine
WO2022140636A1 (fr) Formulations otiques à base de gacyclidine et leurs utilisations
CN120678736A (zh) 一种鼻粘膜给药制剂及其制备方法
Gilger Navigating the myths and folktales of ocular medication-treatment of corneal and ocular surface diseases.
WO2016104705A1 (fr) Agent et procédé permettant d'améliorer des symptômes oculaires subjectifs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251119

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR